Compare ResMed Inc. (RMD) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs iShares Semiconductor ETF — how do they compare? ResMed Inc. trades at $225.5 (market cap $32.61B), while iShares Semiconductor ETF trades at $549.36. The key difference: ResMed Inc. pays a 1.17% dividend while iShares Semiconductor ETF pays none, and iShares Semiconductor ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SOXX | |
|---|---|---|
Market Cap | $32.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $293.73 | $655.01 |
52-Week Low | $182.82 | $241.68 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
SOXX trades at $552.56, up 4.24% with a bullish technical signal from moving averages. The semiconductor ETF faces mixed sentiment as recent news highlights sector rotation away from chips toward software, though major cloud companies' strong earnings support AI infrastructure demand. Technical indicators show neutral oscillators with key resistance at $548.
Outlook remains cautiously optimistic given AI-driven semiconductor demand, but risks include tariff impacts, concentration in 30 stocks, and potential overvaluation after 2026 gains. Institutional buying (Bank of America increased holdings 20.9% in Q1 2026) signals confidence, yet investor caution is warranted amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
